The targeted inhibition of CDC42 expression has been shown to release the antineoplastic ability of effector T cells (Kalim et al., 2022); therefore, more research into the mechanism and effectiveness of CDC42 in tumor evolution and extension is necessary for glioma-targeted therapy. The gene discussed is CDC42; the disease is central nervous system cancer.